Moderna (NASDAQ:MRNA) is preparing to release its quarterly earnings on Friday, 2026-02-13. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Moderna Inc (NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector’s 0.4% YTD return.

Moderna signs a long-term deal with Mexico to build local mRNA production, transfer technology, and supply up to 10 million ...

The biotech has momentum as its quarterly report approaches.

The vaccine maker says the Food and Drug Administration has refused to review its application to sell a new seasonal flu ...

Moderna (MRNA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Moderna beat analysts’ revenue expectations by 32.2% last quarter, reporting revenues of $1.02 billion, down 45.1% year on ...

While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s ...

US stock futures ticked modestly higher late Thursday, attempting to stabilize after a broad market selloff, as investors ...

The First Daily 2X Long ETF for Moderna, Inc. Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long ...

CHONGQING, CHINA - JULY 29: In this photo illustration, a smartphone displays the logo of Moderna Inc. (NASDAQ: MRNA), a biotechnology company known for its mRNA-based vaccines and therapeutics, in ...